Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 10/20 | 0.51 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19899794 | 0.90 | KCNH2 (0.53) | S1PR3FBP1S1PR1RAB9AMAPT | |
| SCHEMBL19914320 | 0.78 | KCNH2 (0.40) | S1PR3FBP1S1PR1RAB9APSMB8 | |
| SCHEMBL21130409 | 0.77 | NPC1 (0.44) | RAB9AMAPTMEN1GAAKMT2A | |
| SCHEMBL24176709 | 0.76 | S1PR3 (0.50) | S1PR3FBP1PIK3CGS1PR1RAB9A | |
| SCHEMBL19899552 | 0.75 | FAAH (0.41) | FBP1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL19899639 | 0.74 | S1PR3 (0.51) | S1PR3FBP1PIK3CGS1PR1RAB9A | |
| SCHEMBL19914235 | 0.74 | S1PR3 (0.51) | S1PR3FBP1PIK3CGS1PR1RAB9A | |
| SCHEMBL19899666 | 0.74 | S1PR3 (0.51) | S1PR3FBP1PIK3CGS1PR1RAB9A | |
| SCHEMBL19914392 | 0.74 | LATS1 (0.36) | RAB9AMAPTMEN1GAAKMT2A | |
| SCHEMBL18028787 | 0.73 | S1PR3 (0.60) | S1PR3FBP1PIK3CGS1PR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-3500567-A1 | ANTIBIOTIC COMPOUNDS | Discuva Ltd. (GB) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | S1PR3 4068/4885FBP1 724/4885PIK3CG 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.